Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.

Macroprolactinomas are pituitary tumours which have been effectively treated medically since the introduction of bromocriptine. The visual function of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor agonist, was evaluate...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Grochowicki, M, Khalfallah, Y, Vighetto, A, Berquet, S, Sassolas, G
Format: Artigo
Jezik:Inglês
Izdano: 1993
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC504657/
https://ncbi.nlm.nih.gov/pubmed/7906538
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki